Kim Drapkin

Ms. Kimberlee C.
Drapkin, CPA, is an Independent Director at Climb Bio, Inc., an Independent Director at LENZ Therapeutics, Inc., an Independent Non-Executive Director at Imugene Ltd., an Independent Director at Acumen Pharmaceuticals, Inc. and a Member at Dana-Farber Cancer Institute, Inc. She is on the Board of Directors at Climb Bio, Inc., Lucy Therapeutics, Inc., LENZ Therapeutics, Inc., Imugene Ltd. and Acumen Pharmaceuticals, Inc. Ms. Drapkin was previously employed as a President, CEO, CFO, Director & PAO by Graphite Bio, Inc., an Independent Director by Kineta, Inc., an Independent Director by Proteostasis Therapeutics, Inc., an Independent Director by Yumanity Therapeutics, Inc., a President, Chief Financial Officer & Treasurer by Jounce Therapeutics, Inc., a Chief Financial Officer & Owner by Kcd Financial Consultants LLC, a Chief Financial Officer by EPIX Pharmaceuticals, Inc., a Chief Financial Officer by Predix Pharmaceuticals Holdings, Inc., a Finance Director by Takeda Oncology Co., a Chief Financial Officer by Avila Therapeutics, Inc., a Chief Financial Officer by Blueprint Medicines Corp., a Chief Financial Officer by Edimer Pharmaceuticals, Inc., a Chief Financial Officer by NinePoint Medical, Inc., a Chief Financial Officer by Predix Pharmaceuticals, Inc., a Principal by PricewaterhouseCoopers LLP, a Chief Financial Officer by Sesen Bio, Inc., a Chief Financial Officer & Treasurer by Voyager Therapeutics, Inc., and a Chief Financial Officer by Warp Drive Bio, Inc. She also served on the board at Yumanity, Inc. She received her undergraduate degree from Babson College.